# Revagenix Inc.

Canonical: https://abierto.us/vendors/revagenix-inc-d98qfzupfxj9

- UEI: D98QFZUPFXJ9
- CAGE: 8B1Y9
- Location: San Mateo, CA
- Awards in window: 2 (22 transactions), $32,815,535 obligated, February 16, 2024 to July 10, 2026

## Awarding agencies

- National Institutes of Health: 2 awards, $32,815,535

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $32,815,535

## Competition

- Full and Open Competition: 2 awards

## Largest awards

- 75N93022C00061 (definitive contract): $23,368,476, National Institutes of Health Niaid. A Novel LPXC Inhibitor with Pan-Resistant Pseudomonas and Burkholderia Activity.. https://www.usaspending.gov/award/CONT_AWD_75N93022C00061_7529_-NONE-_-NONE-/
- 75N93020C00018 (definitive contract): $9,447,059, National Institutes of Health Niaid. To Select a Novel Small Molecule Antibiotic for Clinical Development and Advance IT Through Ind Filing and Phase 1 Clinical Studies.. https://www.usaspending.gov/award/CONT_AWD_75N93020C00018_7529_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/revagenix-inc-d98qfzupfxj9.